Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Testicular Neoplasms 2Seminoma 1Neoplasms 1Hearing Loss 1Anosmia 1

Interventions

Cisplatin 10Etoposide 8Filgrastim 7Paclitaxel 6Ifosfamide 6Carboplatin 6Bleomycin 5Radiotherapy 4Magnetic Resonance Spectroscopy 4pegfilgrastim 3Peripheral Blood Stem Cell Transplantation 3liposomal amphotericin B 2Therapeutics 2Platinum 2Ipilimumab 2Imatinib Mesylate 2Cyclophosphamide 2CTLA-4 Antigen 2sodium thiosulfate 1sargramostim 1lerisetron 1ixabepilone 1aldesleukin 1Vinblastine 1Thiotepa 1Sunitinib 1Specimen Handling 1Ribavirin 1Psychiatric Rehabilitation 1Palivizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Seminoma × Hearing × Genitourinary × Clear all
NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1 Recruiting
44 enrolled
Genitourinary

Testicular Neoplasms, Seminoma, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡